Condition: Hematologic Neoplasms · Influenza · Immunogenicity · Sponsor: Asan Medical Center
This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent (SD-IIV3) vaccines. The study population consists of patients with hematologic malignancies, including those undergoing autologous stem cell transplantation or CAR-T cell therapy. The primary goal is to identify which vaccine strategy elicits the most robust antibody and T cell-mediated immune responses in this severely immunocompromised population
This description comes directly from the study's public registry record.
So Yun Lim, MD, PhD · +82-10-4120-3816 · soyun_lim@amc.seoul.kr
Sung-Han Kim, MD, PhD · +82-2-3010-3305 · shkimmd@amc.seoul.kr
Always discuss trial participation with your own doctor first.
| Asan Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07485855